Aclaris Therapeutics, Inc.
ACRS
$6.18
$0.162.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.75% | 46.50% | 50.84% | -282.88% | -129.47% |
| Total Depreciation and Amortization | -25.35% | -38.15% | -43.74% | -44.51% | -39.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.63% | -85.84% | -85.35% | 1,530.95% | 3,314.14% |
| Change in Net Operating Assets | -96.58% | -83.43% | -75.54% | -106.18% | 755.29% |
| Cash from Operations | -521.34% | -323.85% | -134.68% | -139.80% | 84.50% |
| Capital Expenditure | -84.38% | -179.31% | 8.26% | 84.52% | 90.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 105.91% | 97.62% | 169.60% | -287.10% | -208.45% |
| Cash from Investing | 105.72% | 97.50% | 169.32% | -291.39% | -209.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -27.35% | -27.49% | -- | 8,720.29% | 8,892.36% |
| Repurchase of Common Stock | 30.62% | 33.07% | -9.05% | -711.84% | -273.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.47% | -6.47% | -6.47% | -884.38% | -515.86% |
| Cash from Financing | -29.63% | -29.77% | -107.86% | 1,424,940.00% | 71,559.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -342.80% | 69.06% | 69.89% | -360.07% | 130.88% |